Comment on “Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease”: treatment comparison or treatment sequencing?
Journal of Gastroenterology · 27.05.2026
DOI: 10.1007/s00535-026-02451-z ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Gastroenterology, online erschienen am 27.05.2026. Verfasst von Xichen Fan und 1 weiteren Autor:innen. Beteiligte Einrichtung: China Medical University, Shenyang, China. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- China Medical University, Shenyang, China.
- Department of Radiotherapy, Shanxi Provincial People's Hospital Affiliated to Shanxi Medical University, Taiyuan, 030000, China. zhanggong7446@sxmu.edu.cn.
Zitieren
APA
Fan, X., & Zhang, G. (2026). Comment on “Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease”: treatment comparison or treatment sequencing?. Journal of Gastroenterology. https://doi.org/10.1007/s00535-026-02451-z
Vancouver
Fan X, Zhang G. Comment on “Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease”: treatment comparison or treatment sequencing?. Journal of Gastroenterology. 2026. doi:10.1007/s00535-026-02451-z
BibTeX
@article{Fan2026,
author = {Fan, Xichen and Zhang, Gong},
title = {Comment on “Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease”: treatment comparison or treatment sequencing?},
journal = {Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s00535-026-02451-z}
}
EUVIMED